New and Emerging Trends in Breast Imaging and Treatment

A special issue of Tomography (ISSN 2379-139X).

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 3589

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
Interests: breast imaging; ultrasound; MRI; breast biopsies; machine learning; artificial intelligence

E-Mail Website
Co-Guest Editor
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada
Interests: MRI advanced technique; breast implants imaging; tomosynthesis; health economics

E-Mail Website
Co-Guest Editor
La Sarre Hospital, La Sarre, QC J9Z 2Y9, Canada
Interests: Artificial intelligence; ultrasound; rapid diagnostic unit

E-Mail Website
Co-Guest Editor
Breast Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: outcomes analyses in clinical breast imaging and population-based studies; cost-effectiveness; delivery of care; predictive values; multimodality correlation; minimally invasive biopsy

Special Issue Information

Dear Colleagues,

Breast cancer is the most prevalent cancer diagnosed in women worldwide. It has a major impact on women’s physical and mental health.

In the past 25 years, significant advances in screening, diagnosis and treatment have improved the mortality rate for women with breast cancer, with some studies showing a drop of approximately 40%. Combined with the use of artificial intelligence, the rapid development of medical imaging, tomosynthesis, quality improvement of ultrasound probes, and emerging PET/MR will continue to contribute to better outcomes for women with breast cancer.

This Special Issue is intended to provide an overview of the development of the newest research on AI, machine learning, PET/MR and breast imaging. We encourage researchers to submit original studies, reviews, communications, case studies, and a series of new frontiers in the diagnosis, treatment, and management of breast diseases or even new prevention methods, new software in artificial intelligence or machine learning and deep learning.

Dr. Belinda Curpen
Dr. Anabel Scaranelo
Dr. Romuald Ferre
Dr. Jessica W. T. Leung
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast MRI
  • radiomics
  • AI
  • segmentation
  • breast cancer receptors

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 4838 KiB  
Article
Comparison of 18F-fluorothymidine Positron Emission Tomography/Computed Tomography and 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Breast Cancer
by Mio Mori, Tomoyuki Fujioka, Ryota Ichikawa, Reina Inomata, Leona Katsuta, Yuka Yashima, Emi Yamaga, Junichi Tsuchiya, Kumiko Hayashi, Yuichi Kumaki, Goshi Oda, Tsuyoshi Nakagawa, Iichiroh Onishi, Kazunori Kubota and Ukihide Tateishi
Tomography 2022, 8(5), 2533-2546; https://doi.org/10.3390/tomography8050211 - 11 Oct 2022
Cited by 1 | Viewed by 3130
Abstract
The uptake of 18F-fluorothymidine (18F-FLT) depends on cells’ proliferative rates. We compared the characteristics of 18F-FLT positron emission tomography/computed tomography (PET/CT) with those of 18F-fluorodeoxyglucose (18F-FDG) PET/CT for breast cancer. We prospectively diagnosed patients with breast [...] Read more.
The uptake of 18F-fluorothymidine (18F-FLT) depends on cells’ proliferative rates. We compared the characteristics of 18F-FLT positron emission tomography/computed tomography (PET/CT) with those of 18F-fluorodeoxyglucose (18F-FDG) PET/CT for breast cancer. We prospectively diagnosed patients with breast cancer who underwent 18F-FLT PET/CT and 18F-FDG PET/CT. Subsequently, significant differences and correlation coefficients of the maximum standardized uptake value (SUVmax) in primary breast cancer and axillary lymph nodes were statistically evaluated. We enrolled eight patients with breast cancer. In six treatment-naive patients, the SUVmax for primary lesions showed a significant difference (mean, 2.1 vs. 4.1, p = 0.031) and a strong correlation (r = 0.969) between 18F-FLT and 18F-FDG. Further, although the SUVmax for the axillary lymph nodes did not show a significant difference between 18F-FLT and 18F-FDG (P = 0.246), there was a strong correlation between the two (r = 0.999). In a patient-by-patient study, there were cases in which only 18F-FDG uptake was observed in lymph nodes and normal breasts. Bone metastases demonstrated lower accumulation than bone marrow on the 18F-FLT PET/CT. In conclusion, a strong correlation was observed between the 18F-FLT PET/CT and 18F-FDG PET/CT uptake. Differences in the biochemical characteristics of 18F-FLT and 18F-FDG were reflected in the accumulation differences for breast cancer, metastatic lesions, and normal organs. Full article
(This article belongs to the Special Issue New and Emerging Trends in Breast Imaging and Treatment)
Show Figures

Figure 1

Back to TopTop